Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression.
about
Treatment-resistant Late-life Depression: Challenges and PerspectivesDepressive symptoms increase the risk of progression to dementia in subjects with mild cognitive impairment: systematic review and meta-analysis.Biomarkers for depression: recent insights, current challenges and future prospects.Increased levels of ascorbic acid in the cerebrospinal fluid of cognitively intact elderly patients with major depression: a preliminary study.Altered activation of innate immunity associates with white matter volume and diffusion in first-episode psychosis.Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults.Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment.Plasma and cerebrospinal fluid amyloid-β levels in late-life depression: A systematic review and meta-analysis.Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.Plasma REST: a novel candidate biomarker of Alzheimer's disease is modified by psychological intervention in an at-risk populationSex Differences in the Relationship between Depressive Symptoms and Risk of Amnestic Mild Cognitive Impairment.Episodic memory in depression: the unique contribution of the anterior caudate and hippocampus.Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease.Neurobiological mechanisms of stress resilience and implications for the aged population.Components of the metabolic syndrome and depressive symptoms in community-dwelling older people: the Bambuí Cohort Aging Study.Treatment Emergent Suicidal Ideation in depressed older adults.Divergent Roles of Vascular Burden and Neurodegeneration in the Cognitive Decline of Geriatric Depression Patients and Mild Cognitive Impairment Patients.Neuropsychological functioning in the acute and remitted States of late-life depression.Vascular depression consensus report - a critical update.Treatment Considerations for Depression Research in Older Married Couples: A Dyadic Case Study.Plasma IL-17A levels in patients with late-life depression.The association between insulin resistance, metabolic variables, and depressive symptoms in Mexican-American elderly: A population-based study.Stem Cell Factor (SCF) is a putative biomarker of antidepressant response.Enhanced Molecular Aging in Late-Life Depression: the Senescent-Associated Secretory Phenotype.Immunological biomarkers associated with brain structure and executive function in late-life depression: exploratory pilot study.The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): Rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression.Proteomics for blood biomarker exploration of severe mental illness: pitfalls of the past and potential for the futureAberrant Default Mode Network Underlying the Cognitive Deficits in the Patients With Late-Onset Depression
P2860
Q26783006-642F701D-D843-422E-A3D0-EEC7A30C2BACQ30252001-7B119D7C-DEBD-4AC4-A9ED-E07701221AB6Q33704099-FBEFE0F8-1EDB-4E23-AE08-D3549C21833BQ33799643-1089F4D0-B13F-4811-A7E6-BD4C4C974C5CQ35603078-83783F79-DEEB-423F-9D31-4FC87D114C4BQ35981455-E0D020F8-A21E-4E12-BDD2-AD74FFE054D3Q36910036-ADFA367A-F5FC-4008-8A83-45CE395AFADDQ37403796-FE584823-AD57-4276-8C74-26A7AD57BD30Q38657429-D67491C5-A389-4755-A038-57FB7F1DFF5EQ38741096-A6A012B8-0007-4313-816F-7E9AE0F95485Q38781740-8F49AC2C-F350-40DE-814D-B68E44702A92Q38870882-CE9CBC1B-6B0D-4661-8E8C-649AFDF3D4BCQ38988833-E2519250-17D1-45E6-AE65-AECC0448B6DCQ39311440-5E3A1CFF-D48F-4BD2-9242-FF65D62F85DAQ39504880-0D4F16F8-1B22-4941-A39B-63837A8E3C5BQ39780546-7F177409-3421-4833-AB62-7018CD7D43C8Q41623671-377C5AAC-CF99-44EF-A998-1B71844F3A0BQ41731276-A524B471-0644-4986-87DA-D099B5B0BE46Q42374732-B9E11AC5-2CE7-4C3B-96EA-E370FB29F928Q47103892-9649C008-CC4B-4BDB-9584-D8A99CCD1C7EQ47605434-068BE1A9-6BFC-46E0-AC9C-F86D73C86679Q47765365-F635E18B-B19F-47A7-A14C-D71CED86B19EQ47864124-0918554D-2EC7-4029-8AD2-66C04E5E719AQ47876260-7C47770B-228F-4780-9DF5-1656657C280EQ48004778-B73D6AAC-5282-4B10-9714-3A9229E5CDA0Q52662001-DAABBEA4-F475-4D1A-AD42-A8FA07BCB6D2Q57169146-D940DD68-7016-4A29-ADF7-A8B21F7F1026Q58585194-B2589A4A-65E3-4184-AFB4-DA343B35BAAB
P2860
Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Plasma biosignature and brain ...... rment in late-life depression.
@ast
Plasma biosignature and brain ...... rment in late-life depression.
@en
type
label
Plasma biosignature and brain ...... rment in late-life depression.
@ast
Plasma biosignature and brain ...... rment in late-life depression.
@en
prefLabel
Plasma biosignature and brain ...... rment in late-life depression.
@ast
Plasma biosignature and brain ...... rment in late-life depression.
@en
P2093
P2860
P356
P1433
P1476
Plasma biosignature and brain ...... rment in late-life depression.
@en
P2093
C F Reynolds
J T Becker
M A Butters
P2860
P2888
P304
P356
10.1038/MP.2014.76
P407
P577
2014-08-05T00:00:00Z
P5875
P6179
1012376522